A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07244341
This study is recruiting at 9 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Castration-resistant Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Daiichi Sankyo
- Last updated on ClinicalTrials.gov
- May 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California San Diego Moores Cancer Center · La Jolla, CA
Massachusetts · 2
- Beth Isreal Deaconess Medical Center · Boston, MA
- Dana Farber Cancer Institute · Newton, MA
Michigan · 1
- Cancer & Hematology Center · Grand Rapids, MI
New York · 1
- Northwell Health Cancer Institute (START NY) · Lake Success, NY
South Carolina · 1
- Carolina Urologic Research Center · Myrtle Beach, SC
Texas · 1
- NEXT Oncology · San Antonio, TX
Virginia · 1
- Virginia Cancer Specialists (NEXT Virginia) · Fairfax, VA
Wisconsin · 1
- Medical College Of Wisconsin · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.